Australia's Argent BioPharma set for best day in a year on AusCann deal
19/08/2025 05:09
** Argent Biopharma RGT.AX surges as much as 272.1% to A$0.32; marks biggest intra-day pct gain since August 21, 2024 ** Stocks hits highest since October 24, 2024; eyes fourth straight session of gains ** Drug discovery firm signs binding term sheet to acquire cannabinoid-based therapeutics co AusCann Group for $15 million ** Co to secure Neuvis patented drug-delivery tech, FDA-facing epilepsy pre-clinical data, others under deal ** About 1.8 mln shares traded in stock's busiest day ever ** RGT last up 74.4%, trimming YTD losses to 26.5% (Reporting by Ananya Verma in Bengaluru) ((ananya.verma@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group